BCL9L and breast cancer: We next assessed whether a mutation of the N-terminal domain in β-catenin, which abrogated the interaction with both Bcl9 and Bcl9L on the side of β-catenin, recapitulated the effects of B9/B9L-ΔHD2 in breast cancer progression.